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Abstract. 29 
Introduction: Contingent cell-free (cf) DNA screening on the basis of the first-trimester 30 
combined test (FCT) results has emerged as a cost-effective strategy for screening of 31 
trisomy 21 (T21).  32 
Objectives: To assess performance, patients’ uptake and cost of contingent cfDNA 33 
screening and to compare it to that of the stablished FCT. 34 
Methods: This is a prospective cohort study including all singleton pregnancies attending 35 
to their FCT for screening of T21 at two university hospitals in South Spain. When the 36 
FCT risk was 1:50, there were major fetal malformations or the nuchal translucency 37 
was ≥3.5mm, women were recommended invasive testing (IT); if the risk was between 38 
1:50 and 1:270, women were recommended cfDNA testing and for risks bellow 1:270, 39 
no further testing was recommended. Detection rate (DR), false positive rate (FPR), 40 
patients’ uptake and associated costs were evaluated. 41 
Results: We analyzed 10,541 women, including 46 T21 cases. DR of our contingent 42 
strategy was 89.1% (41/46) at 1.4% (146/10,541) FPR. Uptake of cfDNA testing was 43 
91.2% (340/373) and overall IT rate was 2.0%. The total cost of our strategy was 44 
€1,467,235.7, similar to €1,446,525.7 had cfDNA testing not been available. 45 
Conclusions: Contingent cfDNA screening shows high DR, low IT rate and high uptake 46 
at a similar cost than traditional screening. 47 
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In singleton pregnancies, first-trimester combined test (FCT) for screening of trisomies 54 
21, 18 and 13 using a combination of maternal age, fetal nuchal translucency (NT) 55 
thickness and serum free β-human chorionic gonadotropin (β-hCG) and pregnancy-56 
associated plasma protein A (PAPP-A) has a detection rate of about 90% for trisomy 21 57 
and about 95% for trisomies 18 and 13, at an overall false positive rate (FPR) of 5% [1]. 58 
This method of screening is the first-line screening for aneuploidies in many countries in 59 
Europe, including Spain. Recently, analysis of cell-free (cf) DNA of maternal blood has 60 
been incorporated in clinical practice, providing effective screening for the major 61 
trisomies as early as 10 weeks’ gestation [2]. A recent meta-analysis of clinical validation 62 
and implementation studies reported that the detection rate (DR) of cfDNA testing for 63 
trisomies 21, 18 and 13 are 99.7%, 97.9% and 99.0% respectively, at a combined false 64 
positive rate (FPR) of 0.12 [3]. Therefore, since cfDNA testing is highly effective in 65 
screening for trisomies and it only involves the simple taking of a maternal blood sample, 66 
it could be argued that universal cfDNA screening should be introduced in routine clinical 67 
practice. However, such approach is still limited by the higher cost of the test in 68 
comparison to the traditional FCT. Over the last few years, several studies have been 69 
published assessing the economic impact of different strategies for implementing cfDNA 70 
testing in health care systems [4-6]. An alternative strategy to universal screening is to 71 
offer cfDNA testing contingent on the results of another method of screening used as 72 
first-line screening, preferably the FCT. By this approach, only women at high- and / or 73 
intermediate-risk would be offered cfDNA testing and, therefore, it would still be possible 74 
to retain the main advantage of the test in terms of early results and high performance, 75 
but the cost of such screening program would be considerably lower [7-9]. This strategy 76 
would also allow to retain the advantages of the first-trimester combined assessment 77 
such as pregnancy dating, early detection of major defects and prediction and potential 78 
prevention of a series of pregnancy complications [10]. 79 
 80 
In Spain, like in many countries in Europe, screening for trisomy 21 is carried out by the 81 
FCT, both in private and public settings. However, unlike other European countries, 82 
screening for trisomy 21 is not yet part of the Spanish National Screening Programs and 83 
therefore, there is no regulation to coordinate and monitor it. Recently, the Spanish 84 
Society of Gynecology and Obstetrics (Sociedad Española de Ginecología y Obstetricia, 85 
SEGO) has updated its guidelines to incorporate cfDNA testing as a screening option, 86 
and current recommendation is universal screening by the FCT followed by contingent 87 
cfDNA testing for risks between 1 in 50 and 1 in 250 [11]. The aim of this recommendation 88 
is to reduce the rate of invasive procedures without modifying DR or increasing the cost. 89 
Some Spanish public hospitals have already reported their experience with this approach 90 
[9] but, to the best of our knowledge, no economic evaluation after implementation has 91 
yet been published. 92 
 93 
The objectives of our study are first, to analyse the influence of implementation of cfDNA 94 
contingent screening in the global performance of screening, second, to assess patients’ 95 
acceptability of the cfDNA test and third, to evaluate the difference in costs after 96 
implementing this new screening strategy. 97 
 98 
 99 
MATERIALS AND METHODS 100 
 101 
The data from this study derived from prospective screening for trisomy 21 at 11 to 13 102 
weeks’ gestation by contingent cfDNA testing on the basis of the results from the FCT. 103 
All women with singleton pregnancies attending to their first-trimester hospital visit at one 104 
of two university hospitals in South Spain (Hospital Universitario de Valme in Seville and 105 
Hospital Juan Ramón Jiménez in Huelva) from March 2016 to March 2018 were 106 
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included. Ethics approval was obtained from the Local Research Ethics Committee 107 
(0109-N-16). 108 
 109 
Clinical implementation of cfDNA contingent screening for trisomy 21 110 
In the two participating hospitals, the FCT is routinely performed at 11-13 weeks’ 111 
gestation. During the first-trimester scan, we confirm number of fetuses, check viability, 112 
diagnose major fetal defects, measure crown-rump length (CRL) for pregnancy dating 113 
[12] and fetal NT. This measurements are combined with maternal age and maternal 114 
serum concentrations of free β-hCG and PAPP-A measured at 9–12 weeks’ to calculate 115 
the patient-specific risk for trisomy 21 [1]. If the risk is more than 1 in 270, the mother is 116 
explained that her risk for trisomy 21 is low and she is booked for another scan at 19-21 117 
weeks’ gestation to examine fetal anatomy. If the risk is between 1 in 50 and 1 in 270, 118 
she is classified as high risk and given the options of invasive testing (chorionic villus 119 
sampling or amniocentesis) or cfDNA testing. Finally, if the risk is more than 1 in 50 or if 120 
there are any major fetal malformation or the fetal NT is ≥ 3.5 mm, the mother is 121 
explained that not only the risk of trisomy 21 is increased but also that of other 122 
chromosomal and subchromosomal abnormalities and therefore, she is advised to have 123 
an invasive test with array analysis (figure 1). 124 
 125 
Women opting for cfDNA testing provided written informed consent and maternal blood 126 
(20 mL) was collected into Roche Cell-Free DNA Collection Tubes (Roche, Pleasanton, 127 
CA). The tubes were shipped without any processing to the cfDNA laboratory in Madrid, 128 
Spain. Targeted cfDNA testing for fetal trisomy was performed using the Harmony® 129 
prenatal test. In brief, Harmony® uses digital analysis of selected regions (DANSR) 130 
assays targeting sequences on chromosomes 13, 18, and 21 for chromosome 131 
quantitation and single nucleotide polymorphisms on chromosomes 1 to 12 for fetal 132 
fraction measurement. Products of the DANSR assays are quantified using a custom 133 
microarray. The FORTE (Fetal fraction Optimized Risk of Trisomy Evaluation) algorithm 134 
is used to include fetal fraction in data analysis and provide patient-specific risk 135 
assessments for trisomy [13]. A risk of ≥ 1% is considered to be high probability. In the 136 
study sites, women receiving a low-risk result are reassured that trisomies are unlikely 137 
and they are booked for anomaly scan at 19-21 weeks. However, women receiving a 138 
high-risk result are advised to consider invasive testing for prenatal diagnosis. For the 139 
cases where the cfDNA test does not provide results, women are offered a second draw 140 
and for those cases without results from second analysis, they are advised to have 141 
invasive testing (figure 1). 142 
 143 
Performance of screening 144 
DR and FPR with their confidence intervals (CI) were calculated for both, cfDNA 145 
contingent screening and traditional FCT. Different cut-offs were explored to estimate 146 
performance of the contingent strategy when the group offered cfDNA testing is 147 
increased.   148 
 149 
Pregnancy outcome 150 
Pregnancy outcome was ascertained by two methods: first, prenatal or postnatal 151 
karyotyping and second, neonatal examination by a qualified physician within the first 152 
three days of the newborn’s life. Cases raising any suspicion were followed up at least 6 153 
months after birth. Cases lost to follow up, including those ending up in miscarriage or 154 
stillbirth without karyotyping, were excluded. 155 
 156 
Economic assessment 157 
We performed short-term economic analysis including all procedures carried out until 158 
delivery. For this analysis we took into account only direct costs, including tests and 159 
procedures performed during pregnancy and delivery, as established by the public health 160 
 5 
system of Andalucía, Spain [14], except for the case of the cfDNA test which was 161 
externalised to a private laboratory.  162 
 163 
Statistical analysis 164 
Descriptive data were expressed as median and interquartile range (IQR) and in 165 
proportions (absolute and relative frequencies). Comparisons between treatment groups 166 
were performed by Mann-Whitney U-test or two-tailed χ2-test as appropriate. 167 
 168 





Study population 174 
During the study period a total of 10,794 women attended their first-trimester hospital 175 
visit at one of the two participating hospitals. 10,677 (98.5%) of those accepted FCT for 176 
screening of trisomy 21, 117 (1.1%) declined screening and 136 were lost to follow up. 177 
Maternal and pregnancy characteristics as well as results from FCT and cfDNA test when 178 
performed are shown in table 1. In the study population there were 68 (0.62%) 179 
chromosomal abnormalities, including 46 cases of trisomy 21 (0.43%).  180 
 181 
Performance of contingent screening 182 
Following our strategy, we detected 41 (89.1%; 95% CI: 77.0 to 95.3) of the 46 trisomy 183 
21 cases and 58 (85.3%; 95% CI: 75.0 to 91.8) of the 68 cases of other aneuploidies at 184 
1.4% (146/10,541; 95% CI: 1.2 to 1.6) invasive testing rate in the first trimester of 185 
pregnancy. After including the results from the 19-21 weeks’ anomaly scan, we increased 186 
the detection rate for trisomy 21 to 91.3% (42/46; 95% CI: 79.7 to 96.6) and for the other 187 
aneuploides diagnosed before or after birth, to 94.1% (64/68; 95% CI: 85.8 to 97.7).  188 
Had cfDNA testing not being available, FCT alone would have also detected 89.1% 189 
(41/46; 95% CI: 77.0 to 95.3) of the trisomy 21 cases but at 4.3% (457/10,541; 95% CI: 190 
4.0 to 4.7) FPR. 191 
 192 
Performance of cfDNA testing alone 193 
In total, we carried out 340 cfDNA tests. We did not get a result after the first draw in 17 194 
(5.0%) cases but after repeating the test in all 17 cases, only two (0.6%) cases were left 195 
without a result. The cfDNA test detected all 15 cases of trisomy 21 with no false 196 
positives.  197 
 198 
Women’s preferences on clinical management (table 2) 199 
The screening protocol of our hospitals is shown in figure 1. In 148 (1.4%) cases we 200 
detected any major fetal malformation, fetal NT was ≥ 3.5 mm or the FCT risk was ≥ 1 in 201 
50. In this first group, there were 43 aneuploidies, including 26 cases of trisomy 21. 145 202 
(98.0%) women chose to have an invasive test but 3 (2.0%) opted against it and had 203 
cfDNA testing instead. Among the women having invasive testing, there was one 204 
miscarriage at 16 weeks’ gestation. In 373 (3.5%) cases, the FCT risk was between 1 in 205 
50 and 1 in 270 without major fetal malformations or increased NT. In this second group, 206 
there were 15 cases of trisomy 21. 340 (91.2%) women in this group chose to have 207 
cfDNA testing, 30 (8.0%) chose to have invasive testing and 3 (0.8%) women decided 208 
not to have any further testing. In this group, there were 2 miscarriages at 13 and 20 209 
weeks’ respectively. In 10,156 (95.1%) cases, the FCT risk was less than 1 in 270 without 210 
major fetal malformations or increased NT. In this third group, there were 10 211 
aneuploidies, including five cases of trisomy 21 (one case of spontaneous miscarriage). 212 
In total, we performed 210 (2.0%) invasive procedures, 145 in the first group, 30 in the 213 
second group and 35 in the third one. 214 
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Of the 17 cases that did not receive a result after the first attempt, all women decided to 215 
repeat the test. The two women that did not get a result from the second draw decided 216 
not to do more studies and follow the usual pregnancy care. 217 
 218 
Cost analysis 219 
 220 
Cost of screening of trisomy 21 by our cfDNA contingent strategy was estimated in 221 
€1,467,235.7 and cost / effectiveness was estimated in €22,925.5 (table 3). If cfDNA 222 
testing had not been available, the estimated cost and cost/effectiveness would have 223 
been similar (€1,446,525.7 and €22,601.9 respectively). Therefore, implementation of 224 
cfDNA testing contingently after the FCT only resulted in a marginal 1.4% increase in the 225 
total cost of the program.  226 
 227 
Performance of different strategies of contingent cfDNA testing  228 
We finally evaluated performance and associated costs of contingent screening at 229 




Main findings of the study  234 
In this study we found that first, within our public health system, a strategy in which cfDNA 235 
testing is implemented contingently after the FCT is accepted by 91.2% of the women; 236 
second, our contingent strategy allows to reduce the invasive testing rate from 4.2% to 237 
1.4% for the same DR of about 90%; and third, this strategy can be implemented at a 238 
similar cost than traditional screening.  239 
 240 
Comparison with previous studies 241 
Our results are consistent with those from previous studies, which showed that 242 
contingent screening of aneuploidies by FCT and cfDNA test is feasible and well 243 
accepted by patients [7-9,15,16]. The first study reporting on the performance of this 244 
contingent strategy used a cut-off of 1 in 2500 from the FCT to offer cfDNA testing [15]. 245 
The authors reported that, although this cut-off could potentially increase the DR up to 246 
97% for trisomy 21 and up to 95% for trisomies 18 and 13, it would require that about 247 
24% of the screened population had cfDNA testing [17]. Similarly, had we offered cfDNA 248 
testing to women with a risk of 1 in 2,500 or more, we would have detected 97.8% of the 249 
cases of trisomy 21 and 98.5% of the other aneuploidies by performing the test in about 250 
26% of our population. In contrast, the SEGO proposal aims to ensure a DR of about 251 
90% but only about 4% of the women to require cfDNA testing, as shown in our study. 252 
The main advantage of this strategy is the secondary reduction of invasive tests at a 253 
similar cost. During the study period, our invasive testing rate was 2.0% (210/10,541), 254 
which is considerably lower than our previously reported rate of 4.8% in 2005 to 2010 (p 255 
< 0.0001) [18]. Another Spanish study conducted in a public hospital in Madrid region, 256 
reported only 75% uptake of cfDNA testing within the high-risk group, defined as a risk 257 
of ≥ 1 in 250 at the time of screening [9]. However, this uptake increased from 8% in the 258 
very high-risk group (risks ≥ 1 in 10) to 100% in the less high-risk group (risks between 259 
1 in 150 and 1 in 250), and the uptake of cfDNA testing in the women whose risk was 260 
between 1 in 50 and 1 in 250, was about 90% like in the present study [9].  261 
 262 
Strengths and weaknesses of the study  263 
The main strength of our analysis is the use of real clinical data, collected in fully funded 264 
public hospitals. Thus, these results reflect women’s behaviour in real life regarding 265 
uptake of trisomy 21 screening, cfDNA testing and invasive testing regardless of 266 
economic status and therefore, lead to real inputs for our model. However, although it 267 
was not the aim of our study, the small number of affected pregnancies included did not 268 
allow us to accurately assess the performance of neither the FCT nor the cfDNA test. 269 
 7 
Another limitation is that we only assessed short-term costs for economic evaluation, 270 
acknowledging that indirect costs, although difficult to quantify, are also of great 271 
importance. Additionally, we have not taken into account the costs related to personnel 272 
involved but we believe that both, indirect costs and personnel costs, would be higher in 273 
the strategy without cfDNA testing; first, because sick leave is more likely to happen after 274 
invasive testing than after cfDNA testing, second, because the cost of one or even two 275 
Fetal Medicine specialists performing an invasive procedure is higher than that of a nurse 276 
drawing blood for cfDNA analysis. 277 
 278 
Interpretation  279 
Essentially, there are two options for clinical implementation of cfDNA testing in 280 
screening of the major trisomies: first, universal screening and second, contingent 281 
screening based on the results of first-line screening by another method. Universal 282 
screening would definitely lead to the best performance. However, the high marginal cost 283 
associated leaves this strategy out for most public health systems. Therefore, introducing 284 
cfDNA testing in a contingent fashion seems to be a reasonable alternative. Following 285 
cfDNA testing, the most accurate method for screening of trisomy 21 is the FCT and the 286 
results from our study prove that, only having a good-quality first-trimester scan and FCT, 287 
we can ensure high performance of any contingent screening proposal and keep the 288 
costs as previously determined. When the cost of the test decreases, current cut-offs 289 
may be replaced by lower ones and the proportion of women opting for cfDNA testing 290 
may be expanded; however continuous audit and monitoring of performance and costs 291 
is necessary to keep them stable.  292 
 293 
Conclusions 294 
First, clinical implementation of contingent cfDNA screening following a high-risk result 295 
from the FCT as recommended by the Spanish Society of Obstetrics and Gynecology is 296 
feasible and shows similar DR and costs and lower invasive testing rate than traditional 297 
screening. Second, patients’ uptake of such strategy is high. Third, expanding the group 298 
of patients eligible for cfDNA testing would increase the DR but at the expense of an 299 
increase in the total cost of the program.  300 
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